BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF:

STEVEN GUTTERIDGE ET. AL.

CASE NO.: BB1533USNA APPLICATION NO.: 10/668767

CONFIRMATION NO.: UNKNOWN GROUP ART UNIT: UNKNOWN

EXAMINER: UNKNOWN FILED: SEPTEMBER 23, 2003

FOR: ISOLATION AND USE OF RYANODINE RECEPTORS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PATENT

Sir:

In compliance with 37 CFR 1.97 and 1.98, Applicants bring to the attention of the U.S. Patent and Trademark Office information listed on the enclosed PTO/SB/08. A copy of the information is also enclosed.

Should any fee be required in connection with the filing of this Information Disclosure Statement, please charge such fee to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

Respectfully submitted,

JONATHON O. NARITA
AGENT FOR APPLICANTS
Registration No.: 53,369
Telephone: (302) 695-3127
Facsimile: (302) 695-3125

Dated: February 10, 2004

Enclosures

PTO/SB/92 (08-03)
Approved for use through 07/31/2006. OMB 0561-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on February 17, 2004
Date

Lisa Z. Turner
Signature

LISA Z. TURNER
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

10/668767
BB1533USNA
INFORMATION DISCLOSURE STATEMENT
PTO/SB/08 FORMS (8)
REFERENCES (47)
POSTCARD

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 8

Complete if Known	
Application Number	10/668767
Filing Date	September 23, 2003
First Named Inventor	Steven Gutteridge Et. Al.
Art Unit	UNKNOWN
Examiner Name	UNKNOWN
Attorney Docket Number	BB1533USNA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	1	CHRISTOPHER H. GEORGE ET AL., Ryanodine Receptor Mutations Associated With Stress-Induced Ventricular Tachycardia Mediate Increased Calcium Release in Stimulated Cardiomyocytes, Circ. Res. 93:531-540, 2003	☐
	2	KINYA OTSU ET AL., Chromosome Mapping of Five Human Cardiac and Skeletal Muscle Sarcoplasmic Reticulum Protein Genes, Genomics, 17:507-509, 1993	☐
	3	GIUSEPPE GIANNINI ET AL., The Ryanodine Receptor/Calcium Channel Genes are Widely and Differentially Expressed in Murine Brain and Peripheral Tissues, The Journal of Cell Biology, 128(5):893-904, 1995	☐
	4	DAWEI JIANG ET AL., Enhanced Basal Activity of a Cardiac Ca2+ Release channel (Ryanodine Receptor) Mutant Associated with Ventricular Tachycardia and Sudden Death, Circulation Research 91:218-225, 2002	☐
	5	XUEHONG XU ET AL., Molecular Cloning of cDNA Encoding a Drosophila Ryanodine Receptor and Functional Studies of the Carboxyl-Terminal Calcium Release Channel, Biophysical Journal 78:1270-1281, 2000	☐
	6	HIROSHI TAKESHIMA ET AL., Ca2+-induced Ca2+ release in myocytes from dyspedic mice lacking the type-1 ryanodine receptor, The EMBO Journal 14(13):2999-3006, 1995	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 8

Complete if Known	
Application Number	10/668767
Filing Date	September 23, 2003
First Named Inventor	Steven Gutteridge Et. Al.
Art Unit	UNKNOWN
Examiner Name	UNKNOWN
Attorney Docket Number	BB1533USNA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	7	STEVEN O. MARX ET AL., PKA Phosphorylation Dissociates FKBP12.6 from the Calcium Release Channel (Ryanodine Receptor): Defective Regulation in Failing Hearts, Cell, Vol. 101:365-376, 2000	☐
	8	ANDREW J. DINSMORE ET AL., Characterisation of Antibody Models of the Ryanodine Receptor for Use in High-Throughput Screening, Pestic Sci., Vol. 54:345-352, 1998	☐
	9	TOSHIAKI IMAGAWA ET AL., Expression of Ca2+-Induced Ca2+ Release Channel Activity from Cardiac Ryanodine Receptor cDNA in Chinese Hamster Ovary Cells, J. Biochem., Vol. 112:508-513, 1992	☐
	10	BARBARA BRUCE ET AL., Screening for Ryanodine Receptor Type 2 Mutations in Families with Effort-Induced Polymorphic Ventricular Arrhythmias and Sudden Death, J. of Amer. Coll. of Card., Vol. 40(2):341-349, 2002	☐
	11	GIAN ANTONIO DANELLI ET AL., Genetics of arrhythmogenic right ventricular cardiomyopathy, Current Opinion in Cardiology, Vol. 17:218-221, 2002	☐
	12	MIEKO SHIWA ET AL., Molecular Cloning and characterization of ryanodine receptor from unfertilized sea urchin eggs, Am. J. Physiol. Reg. Integrative Comp., Vol. 282:R727-R737, 2002	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 8

Complete if Known	
Application Number	10/668767
Filing Date	September 23, 2003
First Named Inventor	Steven Gutteridge Et. Al.
Art Unit	UNKNOWN
Examiner Name	UNKNOWN
Attorney Docket Number	BB1533USNA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	13	YASUO OGAWA ET AL., Ryanodine Receptor Isoforms in Excitation-Contraction Coupling, Adv. Biophys., Vol. 36:27-64, 1999	☐
	14	G. LEES ET AL., Cell Culture Approaches to Invertebrate Neuroscience, Academic Press, New York, pp. 123-127, 1988	☐
	15	TOSHIAKI IMAGAWA ET AL., Expression of Ca2+-Induced Ca2+ Release Channel Activity from Cardiac Ryanodine Receptor cDNA in Chinese Hamster Ovary Cells, J. Biochem., Vol. 112:508-513, 1992	☐
	16	MANJUNATHA B. BHAT ET AL., , Functional Calcium release Channel Formed by the Carboxyl-Terminal Portion of Ryanodine Receptor, Biophysical J., Volume 73:1329-1336, 1997	☐
	17	NATASCIA TISO ET AL., The binding of the RyR2 calcium channel to its gating protein FKBP12.6 is oppositely affected by ARVD2 and VTSIP mutations, Biochem. & Biophys. Res. Comm., Vol. 299:594-598, 2002	☐
	18	ISAAC N. PESSAH ET AL., Calcium-Ryanodine Receptor Complex, The J. of Biol. Chem., Vol. 261(19):8643-8648, 1986	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 8

Complete if Known	
Application Number	10/668767
Filing Date	September 23, 2003
First Named Inventor	Steven Gutteridge Et. Al.
Art Unit	UNKNOWN
Examiner Name	UNKNOWN
Attorney Docket Number	BB1533USNA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	19	ELISABETH LEHMBERG ET AL., Similarity of Insect and Mammalian Ryanodine Binding Sites, Pesticide Biochem. & Phys., 48:145-152, 1994	☐
	20	HIROSHI TAKESHIMA ET AL., Isolation and characterization of a gene for a ryanodine receptor/calcium release channel in Drosophila melanogaster, FEBS Letters, 337:81-87, 1994	☐
	21	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 456161, ACCESSION NO: D17389, MARCH 25, 1999, H. TAKESHIMA ET AL., Isolation and characterization of a gene for a ryanodine receptor/calcium release channel in Drosophila melanogaster	☐
	22	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 1871446, ACCESSION NO: D45899, DECEMBER 25, 2002, Y. SAKUBE ET AL., An abnormal ketamine response in mutants defective in the ryanodine receptor gene ryr-1 (unc-68) of Caenorhabditis elegans	☐
	23	YASUJI SAKUBE ET AL., An Abnormal ketamine Response in Mutants Defective in the Ryanodine Receptor Gene ryr-1 (unc-68) of Caenorhabditis elegans, J. Mol. Biol., 267:849-864, 1997	☐
	24	ELENA PUENTE ET AL., Identification of a polymorphic ryanodine receptor gene from Heliothis virescens (Lepidoptera: Noctuidae), Insect Biochem. & Mol. Biol., Vol. 30:335-347, 2000	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 8

Complete if Known	
Application Number	10/668767
Filing Date	September 23, 2003
First Named Inventor	Steven Gutteridge Et. Al.
Art Unit	UNKNOWN
Examiner Name	UNKNOWN
Attorney Docket Number	BB1533USNA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	25	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 17352471, ACCESSION NO: 476994, DECEMBER 10, 2003, M. D. ADAMS ET AL., The genome sequence of Drosophila Melanogaster	☐
	26	MARK D. ADAMS ET AL., The Genome Sequence of Drosophila Melanogaster, Science, Vol. 287:2185-2195,, 2000	☐
	27	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 21301556, ACCESSION NO: EAA17301, MAY 31, 2002, UNKNOWN AUTHOR, UNKNOWN TITLE	☐
	28	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 1871447, ACCESSION NO: BAA08309, DECEMBER 25, 2002, Y. SAKUBE ET AL., An abnormal ketamine response in mutants defective in the ryanodine receptor gene ryr-1 (unc-68) of Caenorhabditis elegans	☐
	29	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 18656155, ACCESSION NO: BAB84714, FEBRUARY 14, 2002, M. SHIWA ET AL., Molecular cloning and characterization of ryanodine receptor from unfertilized sea urchin eggs	☐
	30	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 13569850, ACCESSION NO: NP076357, DECEMBER 21, 2003, H. MASUMIYA ET AL., The mouse sino-atrial node expresses both the type 2 and type 3 Ca(2+) release channels/ryanodine receptors	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 8

Complete if Known	
Application Number	10/668767
Filing Date	September 23, 2003
First Named Inventor	Steven Gutteridge Et. Al.
Art Unit	UNKNOWN
Examiner Name	UNKNOWN
Attorney Docket Number	BB1533USNA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	31	HARUKO MASUMIYA ET AL., The mouse sino-atrial node expresses both the type 2 and type 3 Ca(2+) release channels/ryanodine receptors, FEBS Letters, Vol. 553:141-144, 2003	☐
	32	PATRICK MOST ET AL., Transgenic Overexpression of the Ca2+-binding Protein S100A1 in the Heart Leads to Increased in Vivo Myocardial Contractile Performance, J. of Biol. Chem., Vol. 278(36):33809-33817, 2003	☐
	33	HUANG-TIAN YANG ET AL., The ryanodine receptor modulates the spontaneous beating rate of cardiomyocytes during development, PNAS, Vol. 99(14):9225-9230, 2002	☐
	34	ANNE-VALERIE FAURE ET AL., Developmental expression of the calcium release channels during early neurogenesis of the mouse cerebral cortex, European J. of Neuroscience, Vol. 14:1613-1622, 2001	☐
	35	MINGCAI ZHAO ET AL., Molecular Identification of the Ryanodine Receptor Pore-forming Segment, J. of Biol. Chem., Vol. 274(37):25971-25974, 1999	☐
	36	HIROSHI TAKESHIMA ET AL., Embryonic lethality and abnormal cardiac myocytes in mice lacking ryanodine receptor type 2, The EMBO J., Vol. 17(12):3309-3316, 1998	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 8

Complete if Known	
Application Number	10/668767
Filing Date	September 23, 2003
First Named Inventor	Steven Gutteridge Et. Al.
Art Unit	UNKNOWN
Examiner Name	UNKNOWN
Attorney Docket Number	BB1533USNA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	37	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 1245376, ACCESSION NO: AAA93465, APRIL 2, 1996, J. NAKAI ET AL., Primary structure and functional expression from cDNA of the cardiac ryanodine receptor/calcium release channel	☐
	38	JUNICHI NAKAI ET AL., Primary structure and functional expression from cDNA of the cardiac ryanodine receptor/calcium release channel, FEBS Vol. 271(1,2):169-177, 1990	☐
	39	NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION GENERAL IDENTIFIER NO. 4506757, ACCESSION NO: NP001026, DECEMBER 23, 2003, C.H. GEORGE ET AL., Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes	☐
	40	CHRISTOPHER H. GEORGE ET AL., Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes, J. of Biol. Chem., Vol. 278(31):28856-28864, 2003	☐
	41	JING ZHANG ET AL., Three-dimensional Localization of Divergent Region 3 of the Ryanodine Receptor to the Clamp-shaped Structures Adjacent to the FKBP Binding Sites, J. Biol. Chem., Vol. 278(16):14211-14218, 2003	☐
	42	HARUKO MASUMIYA ET AL., Localization of the 12.6-kDa FK506-binding Protein (FKBP12.6) Binding Site to the NH2-terminal Domain of the Cardiac Ca2+ Release Channel (Ryanodine Receptor), J. Biol. Chem., Vol. 278(6):3786-3792, 2003	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 8

Complete if Known	
Application Number	10/668767
Filing Date	September 23, 2003
First Named Inventor	Steven Gutteridge Et. Al.
Art Unit	UNKNOWN
Examiner Name	UNKNOWN
Attorney Docket Number	BB1533USNA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	43	JIEFEI TONG ET AL., Caffeine and Halothane Sensitivity of Intracellular Ca2+ Release is Altered by 15 Calcium Release Channel (Ryanodine Receptor) Mutations Associated with Malignant Hyperthermia and/or Central Core Disease, J. Biol. Chem., Vol. 272(42):26332-26339, 1997	☐
	44	S. R. WAYNE CHEN ET AL., Antibodies as Probes for Ca2+ Activation Sites in the Ca2+ Release Channel (Ryanodine Receptor) of Rabbit Skeletal Muscle Sarcoplasmic Reticulum, J. Biol. Chem., Vol. 268(18):13414-1421, 1993	☐
	45	CELETTA CALLAWAY ET AL., Localization of the High and Low Affinity [3H]Ryanodine binding Sites on the Skeletal Muscle Ca2+ Release Channel, J. Biol. Chem., Vol. 269(22):15876-15884, 1994	☐
	46	MELANIE SCHMITT ET AL., Binding Sites for Ca2+-Channel Effectors and Ryanodine in Periplaneta americana - Possible Targets for New Insecticides, Pestic Science, Vol. 48:375-385, 1996	☐
	47	RICHARD E.A. TUNWELL ET AL., The human cardiac muscle ryanodine receptor-calcium release channel: identification, primary structure and topological analysis, Biochem. J. Vol. 318:477-487, 1996	☐
			☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.